MaxCyte (MXCT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte, Inc. has announced a significant change in its shareholding structure as BlackRock, Inc. reported an increase in its voting rights to 8.75%, up from 9.37%. This adjustment underscores BlackRock’s strategic maneuvers in the financial market, marking its influence in the biopharmaceutical sector.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.